BioSpace News Archive

Halia Therapeutics announced the opening of its new 20,000 square foot headquarters located at The Summit, on 3900 North Traverse Mountain Blvd., in Lehi, Utah.

Protagonist Therapeutics, Inc. reported that on August 15, 2023, it issued inducement awards to Christine Rocha, the Company’s recently hired Vice President, Clinical Operations, in accordance with the terms of Ms. Rocha’s employment offer letter.

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that China’s National Medical Products Administration (NMPA) has approved SINTBILO®.

Bioretec Ltd, a pioneering company dedicated to advancing orthopedic biodegradable implants, has refined and expanded its esteemed Scientific Advisory Board.

ChemDiv Inc, a global leader in drug discovery and drug development solutions, shares the progress in the development of its cutting-edge biology facility at Biocant Park, Cantanhede, Portugal.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the achievement of First-Patient-In for the company-sponsored Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma patients.

FesariusTherapeutics, Inc. today announced they have been awarded an $800,000 SBIR CRP grant to advance the development of their novel DermiSphere™ dermal regenerative template to treat full thickness skin loss.

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel).

Silence Therapeutics plc today reported its financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.